Immunai Technologies joined the Unicorn Club on October 27, 2021, after raising a $215 million Series B funding round led by Koch Disruptive Technologies, valuing the company at about $1 billion. Headquartered in the United States, Immunai develops a next-generation immunomodulatory therapeutics platform built around its proprietary engine, AMICA (Annotated Multiomic Immune Cell Atlas), which combines multi-omic single-cell analysis, machine learning, and functional genomics to accelerate drug discovery and development for immune-modulating medicines. The company has raised a total of approximately $295 million in funding to date and employs between 51 and 200 people (as of July 1, 2024).
Keep reading to learn more about how Immunai is mapping the immune system to transform therapeutics via high‑resolution data and AI‑driven insights.
What Is Immunai Technologies and What Does It Do?
Founded in 2018, Immunai Technologies is a biotech company focused on decoding the human immune system through its AMICA engine. This annotated multi-omic immune cell atlas integrates single-cell genomics, proteomics, epigenetics, and machine learning.
By combining this immune‑cell‑level data with functional genomics, Immunai enables pharmaceutical and biotech partners to identify novel immunotherapy targets, predict patient responses and streamline drug development. Its platform supports applications in immuno‑oncology, autoimmune diseases and inflammatory conditions.
How Much Funding Has Immunai Technologies Raised?
- Series B
- Amount Raised: $215 M
- Date: October 27, 2021
- Lead Investor: Koch Disruptive Technologies
- Valuation: ~$1 B
- Purpose: To expand its immune‑atlas capabilities, build drug‑discovery partnerships, and scale its multi‑omic platform.
- Earlier Rounds (Seed to Series A)
- Cumulative Funding: ~$80 M (as of Feb 2021)
- Key Investors: Catalio Capital Management, Alexandria Venture Investments, Viola Ventures, TLV Partners
- Purpose: Build foundational single‑cell genomics technology and the AMICA dataset.
Total Funding Raised: ~$295 M
Latest Funding Date: October 27, 2021
Latest Valuation: ~$1 B
Employee Count: 51‑200 (as of July 1, 2024)
Key Investors
- Koch Disruptive Technologies
- Details: Investment arm of Koch Industries that backs transformative companies in technology and healthcare.
- Focus Areas: Industrial tech, biotech platforms, and high‑growth disruptive services.
- Catalio Capital Management
- Details: Life sciences investment firm supporting biotech and therapeutic discovery companies.
- Focus Areas: Genomics, immunotherapy, functional genomics.
- Alexandria Venture Investments
- Details: Strategic investment arm of Alexandria Real Estate Equities, focusing on life science enterprise growth.
- Focus Areas: Biotech innovation, cell & gene therapy, multi‑omic discovery.
Where Is Immunai Technologies’ Headquarters?
Immunai Technologies is headquartered in the United States, with offices in New York City, Tel Aviv, Prague, and Zurich. Its headquarters supports research, development and partnerships with biotech and pharmaceutical companies globally.
What’s Next for Immunai Technologies?
Immunai is set to deepen its immune-mapping platform, expand clinical partnerships, and move toward therapeutic development using its AMICA dataset and AI-driven engine. The company aims to accelerate drug discovery in immunotherapy, autoimmune, and inflammatory diseases, scale its functional genomics capabilities, and monetise its findings through collaborations with pharmaceutical partners.
Get Investor & Funding Insights with TexAu
TexAu provides verified investor and funding data for companies like Immunai Technologies. Explore insights on genomics, biotech platforms and next‑generation life‑science technologies.
Sign up for Free on TexAu to access real‑time investor and funding intelligence.
